OSE Immunotherapeutics SA/€OSE
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About OSE Immunotherapeutics SA
OSE Immunotherapeutics SA is a biotechnology company focused on the research and development of immunotherapies in the fields of immune-oncology, autoimmune diseases, and transplantation. The company aims to innovate through its pipeline, which includes products such as Tedopi, a therapeutic vaccine for non-small cell lung cancer, and CoVepiT, a COVID-19 vaccine. Founded in 2012 and headquartered in Nantes, France, OSE Immunotherapeutics combines strong scientific expertise with a strategic emphasis on building a diversified portfolio of advanced clinical trials. The company's competitive strength lies in its proprietary technologies and strategic partnerships, enhancing its capabilities to address significant unmet medical needs globally.
Ticker
€OSE
Sector
Primary listing
PAR
Employees
64
Headquarters
Website
OSE Metrics
BasicAdvanced
€88m
-
-€1.48
0.82
-
Price and volume
Market cap
€88m
Beta
0.82
52-week high
€7.63
52-week low
€3.00
Average daily volume
30k
Financial strength
Current ratio
1.285
Quick ratio
1.191
Long term debt to equity
88.767
Total debt to equity
106.388
Interest coverage (TTM)
-13.29%
Profitability
EBITDA (TTM)
-37.333
Gross margin (TTM)
88.70%
Net profit margin (TTM)
-1,824.86%
Operating margin (TTM)
-1,392.98%
Effective tax rate (TTM)
-0.74%
Revenue per employee (TTM)
€40,000
Management effectiveness
Return on assets (TTM)
-23.10%
Return on equity (TTM)
-82.32%
Valuation
Price to revenue (TTM)
30.727
Price to book
2.46
Price to tangible book (TTM)
-8.51
Price to free cash flow (TTM)
-2.423
Free cash flow yield (TTM)
-41.28%
Free cash flow per share (TTM)
-1.531
Growth
Revenue change (TTM)
-97.86%
Earnings per share change (TTM)
-215.82%
3-year revenue growth (CAGR)
-54.00%
10-year revenue growth (CAGR)
84.03%
3-year earnings per share growth (CAGR)
20.77%
10-year earnings per share growth (CAGR)
9.62%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs